Pfizer's CEO Sends a Warning to Eli Lilly. Is the Stock a Buy?

Oncology is the largest therapeutic area in the pharmaceutical industry by sales, but right now, weight management is the hottest. This market is predicted to grow rapidly in the next decade, handsomely rewarding any drugmaker that establishes itself as a leader in the field.Right now, that's none other than Eli Lilly (NYSE: LLY). However, others are looking to challenge its dominance. Recent comments from Pfizer's (NYSE: PFE) CEO, Albert Bourla, suggest it could become one of the companies that successfully carve out a niche in the weight management space. Let's see what Bourla said, and what it means for investors.Image source: Getty Images.Continue readingWeiter zum vollständigen Artikel bei MotleyFool Weiter zum vollständigen Artikel bei MotleyFool